Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis

Shock

Volumn 37, Issue 2, 2012, Pages 170-176

  Maybauer, Marc O ^a,b,c   Maybauer, Dirk M ^a,b   Fraser, John F ^c   Westphal, Martin ^a   Szabó, Csaba ^a   Cox, Robert A ^a   Hawkins, Hal K ^a   Traber, Lillian D ^a   Traber, Daniel L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

3 nitrotyrosine; Airway; hypotension; nitric oxide; peroxynitrite; shock

Indexed keywords

3 NITROTYROSINE; CEFTAZIDIME; DROTRECOGIN; MALONALDEHYDE; MYELOPEROXIDASE; RINGER LACTATE SOLUTION;

ADULT RESPIRATORY DISTRESS SYNDROME; AIRWAY OBSTRUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLE; BRONCHUS; CARDIOPULMONARY FUNCTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUID RESUSCITATION; HEART; HEART INDEX; HEART RATE; HEMATOCRIT; LUNG; MEAN ARTERIAL PRESSURE; NONHUMAN; ONCOTIC PRESSURE; OXYGEN TENSION; SEPSIS; SHEEP; SYSTEMIC VASCULAR RESISTANCE; URINE VOLUME;

ANIMALS; BLOOD GAS ANALYSIS; CEFTAZIDIME; FEMALE; HEMODYNAMICS; HUMANS; LUNG; MALE; MYOCARDIUM; OXYGEN; PEROXIDASE; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SHEEP; TREATMENT OUTCOME; TYROSINE;

EID: 84856203466     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31823ca8ee     Document Type: Article

References (35)

1. Shirani KZ, Pruitt BA Jr, Mason AD Jr: The influence of inhalation injury and pneumonia on burn mortality. Ann Surg 205:82-87, 1987. (Pubitemid 17225029)
2. Porzecanski I, Bowton DL: Diagnosis and treatment of ventilator- associated pneumonia. Chest 130:597-604, 2006. (Pubitemid 44267034)
3. Maybauer MO, Maybauer DM, Herndon DN: Incidence and outcomes of acute lung injury. N Engl J Med 354:416-417, author reply 416-417, 2006. (Pubitemid 43145071)
4. Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK, Herndon DN, Traber LD, Traber DL: A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med 30:2083-2090, 2002.
5. Deitch EA: Rodent models of intra-abdominal infection. Shock 24(Suppl 1): 19-23, 2005.
6. Maybauer MO, Maybauer DM, Traber LD, Westphal M, Enkhbaatar P, Morita N, Jodoin JM, Heggers JP, Herndon DN, Traber DL: Gentamicin improves hemodynamics in ovine septic shock after smoke inhalation injury. Shock 24:226-231, 2005. (Pubitemid 41279486)
7. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Cox RA, Huda R, Nakano YY, Enkhbaatar P, Hawkins HK, et al.: Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock. Intensive Care Med 33:1219-1227, 2007. (Pubitemid 47036894)
8. Nakano Y, Maybauer MO, Maybauer DM, Enkhbaatar P, Traber DL: A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock. Burns 36:1050-1058, 2010.
9. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, et al.: Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 34:2432-2438, 2006. (Pubitemid 44262031)
10. Maybauer MO, Kikuchi Y, Westphal M, Maybauer DM, Nishida K, Traber LD, Westphal-Varghese BB, Morita N, Enkhbaatar P, Herndon DN, et al.: Effects of manganese superoxide dismutase nebulization on pulmonary function in an ovine model of acute lung injury. Shock 23:138-143, 2005. (Pubitemid 40222949)
11. Maybauer DM, Maybauer MO, Traber LD, Westphal M, Nakano YY, Enkhbaatar P, Morita N, Herndon DN, Traber DL: Effects of severe smoke inhalation injury and septic shock on global hemodynamics and microvascular blood flow in sheep. Shock 26:489-495, 2006. (Pubitemid 44632279)
12. Waerhaug K, Kirov MY, Kuzkov VV, Kuklin VN, Bjertnaes LJ: Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep. Crit Care 12:R146, 2008.
13. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebretsen OC, Ytrehus K, Bjertnaes LJ: Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 12:R104, 2008.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez- Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001. (Pubitemid 32204987)
15. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, et al.: Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 285:L240-L249, 2003. (Pubitemid 36736487)
16. Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, Herndon DN, Schmalstieg FC, Traber DL, Hawkins HK: Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol 29: 295-302, 2003. (Pubitemid 37093987)
17. Maybauer MO, Maybauer DM, Fraser JF, Szabo C, Westphal M, Kiss L, Horvath EM, Nakano Y, Herndon DN, Traber LD, et al.: Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock. Crit Care 14:R217, 2010.
18. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 161:454-462, 2000. (Pubitemid 30129452)
19. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952-961, 2005. (Pubitemid 40638163)
20. Zarbock A, Singbartl K, Ley K: Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116: 3211-3219, 2006. (Pubitemid 44878635)
21. Szabo C, Modis K: Pathophysiological roles of peroxynitrite in circulatory shock. Shock 34(Suppl 1):4-14, 2010.
22. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824, 1994. (Pubitemid 24082248)
23. Husari AW, Khayat A, Awdeh H, Hatoum H, Nasser M, Mroueh SM, Zaatari G, El-Sabban M, Dbaibo GS: Activated protein C attenuates acute lung injury and apoptosis in a hyperoxic animal model. Shock 33:467-472, 2010.
24. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87:642-647, 1996. (Pubitemid 26030319)
25. Wang Z, Su F, Rogiers P, Vincent JL: Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 35: 2594-2600, 2007. (Pubitemid 351339022)
26. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, et al.: Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 178: 618-623, 2008.
27. Cantin A, Woods DE: Protection by antibiotics against myeloperoxidasedependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 91:38-45, 1993. (Pubitemid 23037250)
28. Kalil AC, Coyle SM, Um JY, et al.: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21:222-229, 2004.
29. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL: Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31:1573-1576, 2005. (Pubitemid 41598671)
30. Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B: Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth Analg 101:488-498, 2005. (Pubitemid 41045235)
31. Pacher P, Szabo C: Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173:2-13, 2008. (Pubitemid 351947950)
32. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S: Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 30:894-899, 2002. (Pubitemid 34297814)
33. Takakura K, Xiaohong W, Takeuchi K, Yasuda Y, Fukuda S: Deactivation of norepinephrine by peroxynitrite as a new pathogenesis in the hypotension of septic shock. Anesthesiology 98:928-934, 2003. (Pubitemid 36373228)
34. Macarthur H, Couri DM, Wilken GH, Westfall TC, Lechner AJ, Matuschak GM, Chen Z, Salvemini D: Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med 31:237-245, 2003. (Pubitemid 36151178)
35. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008.